CD276

Overview

CD276 (also known as B7-H3) is an immune checkpoint molecule overexpressed on tumor cells and tumor vasculature across many solid tumor types. Unlike other B7-family members, its receptor on T cells remains incompletely characterized. B7-H3 overexpression is associated with poor prognosis and immune evasion; it is a therapeutic target for antibody-drug conjugates (ADCs).

Alterations observed in the corpus

• B7-H3 overexpressed checkpoint in NPC; ADC YL201 achieved ORR 48.6% in NPC sub-cohort (n=70) PMID:24952746

Cancer types (linked)

• NPC: CD276/B7-H3 overexpressed; YL201 ADC ORR 48.6% (n=70) PMID:24952746

Co-occurrence and mutual exclusivity

No data in current corpus.

Therapeutic relevance

• YL201 (anti-CD276 ADC) — ORR 48.6% in NPC sub-cohort PMID:24952746

Open questions

No conflicts in current corpus.

Sources

• PMID:24952746

This page was processed by entity-page-writer on 2026-05-11.